Additional clinical trial should be necessary during postmarketing surveillance

Drug makers are obligated to conduct the additional clinical trial of a pharmaceutical drug in the period of postmarketing surveillance (PMS), under the newly revised regulation over re-examination of the drug, according to the Korea Food and Drug Administration.

The drug agency said the newly PMS regualtion can further refine, or confirm or deny, the safety of a drug after it is used in the...